Medical Appropriateness and the Economics of Clinical Pathways
Previous columns have explored various business-related aspects of clinical pathways in the US health care market. However, one aspect that has received less attention is how guidelines and pathways have emerged as an important part of the health care access and affordability conversation, particularly regarding health insurance or out-of-pocket costs. Understanding this relationship requires examining how the concept of medical appropriateness has shaped health care coverage and reimbursement decisions over time.
The concept of medical appropriateness for health care dates back to federal medical cost controls and professional standards established in the mid-1960s. Through successive federal legislation and regulatory actions, this concept has evolved to govern various aspects of medical care decision-making, care quality, and outcomes assessment. Like most aspects of health care, this oversight originated from inpatient or hospital-based care delivery but has expanded to affect all aspects of care delivery where public or private sector funds are used. Initially starting with medical care, it has evolved to encompass the management of nearly all health care services, including pharmacy and biopharmaceuticals.
Legislative Milestones and Managing Medical Appropriateness
As Congress sought to address the growing need for access and affordability in health care post-WWII, including affordability, some well-intended laws were passed that seemed to offer solutions. Not unexpectedly, as health care rapidly evolved in complexity and its ability to offer life-altering or life-saving services, additional legislation was passed. Some of the key federal law milestones in establishing medical appropriateness include the following:
- Social Security Amendments of 1965: In addition to creating Medicare and Medicaid, these amendments required hospitals to establish utilization review (UR) committees to determine whether admissions were medically necessary.1,2
- Social Security Amendments of 1972: Established Professional Standards Review Organizations (PSROs), later called Professional Review Organizations (PROs), allowing community doctors to review the necessity and quality of federally funded health services delivered in their local communities.2
- Tax Equity and Fiscal Responsibility Act (TEFRA) of 1982: Introduced the Prospective Payment System (PPS) and Diagnosis-Related Groups (DRGs), which tied inpatient hospital reimbursement to the already established regulatory definition of appropriate inpatient care duration and level of care required.1,2
- Emergency Medical Treatment and Labor Act (EMTALA) of 1986: Required hospital emergency departments to provide stabilizing treatment for patients regardless of ability to pay, thereby legally defining appropriate emergency care before patient transfer or discharge.2
- Patient Protection and Affordable Care Act of 2010: Expanded appeals processes for denied claims, reinforcing patients’ rights to challenge third-party payer determinations of medical necessity.3
Today, regulatory agencies continue to determine how best to implement existing legislation, interpret regulations in response to new technologies or therapies, and recommend additional legislation to address non-regulatory issues. After over 60 years, many of the same or similar problems remain.
State legislation generally is more restrictive than federal law, leaving states to face certain issues regarding insurance or entitlement programs.4 For example, hospital medical care costs generally represent the largest reimbursement category, but pharmaceutical care costs have also grown rapidly.5 Both before and since the pandemic, pharmacy benefit costs have continued to complicate the funding formulas used for underwriting overall health care coverage risk.6 As a result, determining medical appropriateness continues to grow in importance for effective clinical and fiscal management.
Guidelines vs Pathways as the Foundation for Medical Appropriateness
Foundational guidance for determining or management of medical appropriateness generally comes from clinical guidelines and pathways. Guidelines offer broad, scientifically based, and medically reviewed recommendations to ensure patients or health insurance beneficiaries receive the care they need within the proper timeframe to achieve expected outcomes throughout the patient care journey. These guidelines can be developed nationally or internationally by expert panels that allow for clinical judgement based on individual patient factors. Typically, they are created by medical societies, government agencies, independent expert panels, commercial and insurance organizations, and nonprofit research groups.7
Clinical pathways (CPs) are tools used to guide evidence-based health care delivery. They translate clinical practice guideline recommendations into structured, multidisciplinary clinical processes of care (care plans) for delivery within the culture and environment of a healthcare organization, such as a health system institution, managed care organization, or health insurer. CPs are specific, prescriptive, and standardized by the organization. They dictate operational steps intended to optimize care and reduced variation in routine care, thereby improving the quality of care delivered.8,9
Balancing Medical Appropriateness and Financial Responsibility
There is long history for the interplay between delivering clinical care and funding that clinical care in a responsible manner, known as fiduciary responsibility. History does repeat itself, and government driven solutions from decades or years ago require updating, additions, elimination, or rewriting to address the evolving state of clinical care delivery in a fiscally responsible manner.
As care delivery moved from the community into hospitals, it became easier to solve care delivery issues until the new century arrived. Toward the end of the last century, there was a resurgence in home health care and hospice, and this shift in where care is delivered has accelerated in the current century, driven largely by fiscal efficiencies. Employers, patients, and entrepreneurial providers have developed various community-based care solutions, including efforts by health systems to provide end-to-end medical care.
The common thread throughout the history of health insurance and legal jurisprudence governing health care delivery and reimbursement has been determining medical appropriateness. Guidelines and pathways will continue to be important tools as the current US efforts to address health care access and affordability unfold.
Could one direction for the market be to offer only a single, integrated benefit package? In this decade and next, as therapies alone can cost plans millions of dollars, we have moved far beyond the health care cost landscape of the 1960s. As new technologies and therapies emerge from research to marketed products, these two interrelated tools are likely to grow in importance as the financial stakes continue to rise each year.
Clinical Pathway Categories: Business and Infrastructure & Innovation
This column examines the evolving role of evidence-based clinical guidelines and pathways in supporting medical appropriateness, standardizing care delivery, and strengthening the infrastructure needed for efficient, high-quality oncology care. From a business perspective, it highlights how clinical pathways can support fiscally responsible decision-making, reduce unwarranted care variation, and balance treatment appropriateness with health care affordability and access.
References
- Tulchinsky TH, Varavikova EA. Health technology, quality, law, and ethics. In: Tulchinsky TH, Varavikova EA, eds. The New Public Health. 3rd ed. Academic Press; 2014:771-819. Accessed August 19, 2026. https://www.sciencedirect.com/science/chapter/monograph/pii/B978012415766800015X
- Institute of Medicine (US) Committee on Utilization Management by Third Parties. Origins of Utilization Management. In: Gray BH, Field MJ, eds. Controlling Costs and Changing Patient Care? The Role of Utilization Management. National Academies Press (US); 1989.
- National Patient Rights Authority. History of patient rights in the United States. Accessed August 19, 2026. https://nationalpatientrightsauthority.com/history-of-patient-rights-in-the-us/
- Harker L, Woolf B, Guerra-Cardus L, Sharer B. State legislative sessions highlight choice between protecting coverage and deepening harm after federal Medicaid cuts. Center on Budget and Policy Priorities. Published August 4, 2026. Accessed August 19, 2026. https://www.cbpp.org/research/health/state-legislative-sessions-highlight-choice-between-protecting-coverage-and
- AHIP. Experts agree: high and rising medical costs causing affordability crisis for consumers. Published September 17, 2026. Accessed August 19, 2026. https://www.ahip.org/news/articles/experts-agree-high-and-rising-medical-costs-causing-affordability-crisis-for-consumers
- Rose K. Pharmacy trends shaping costs and PBM choices: practical steps to evaluate pbms, use biosimilars, and control rising drug costs without cutting benefits. Marsh McLennan Agency. Published April 14, 2026. Accessed August 19, 2026. https://www.marshmma.com/us/locations/minnesota/minneapolis/pharmacy-trends.html
- Morizane T, Kawai F, Kojimahara N. Proposed new definitions of practice guidelines for health and health care. JMA J. 2025;8(4):1384-1387. doi:10.31662/jmaj.2025-0066
- Böckmann B, Heiden K. Extracting and transforming clinical guidelines into pathway models for different hospital information systems. Health Inf Sci Syst. 2013;1:13. doi:10.1186/2047-2501-1-13
- Jenkins F, Jones R. Care pathways and the allied health professional. In: Jones R, Jenkins F, eds. Key Tools and Techniques in Management and Leadership of the Allied Health Professions. CRC Press; 2011:171-197.
